Skip to contentL
Lipella Pharmaceuticals Inc.
L
LIPOLipella Pharmaceuticals Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q3 2024 Net Income-$1.25M-$1.25MN/M vs Q3 2024 EPS Diluted-$0.28-$0.28N/M vs Q3 2024 Operating Income-$1,274,272N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipella Pharmaceuticals Inc. · CIK 1347242 · Engraved from SEC EDGAR
Operating Cash Flowderived-$926,057N/M ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end